SIRPA and neoplasm: The above findings suggest that blocking the SIRP-α-CD47 signaling pathway with monoclonal antibodies or small-molecule inhibitors can effectively block CSC–TAM interaction, thereby inhibiting the progression of CSCs and reducing the tumor burden in vivo.